An apoa-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration

International Journal of Biological Sciences

Volumn 5, Issue 5, 2009, Pages 489-499

  Chen, Xun ^a   Burton, Charlotte ^a   Song, Xuelei ^a   Mcnamara, Lesley ^a   Langella, Annunziata ^a   Cianetti, Simona ^a   Chang, Ching H ^a   Wang, Jun ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Apoe; Atherosclerosis; D 4f; Hdl; Lcat; Lipoprotein; Rct

Indexed keywords

MUS;

ABC TRANSPORTER; ABC TRANSPORTER A1; APOLIPOPROTEIN A1; D 4F PEPTIDE; D-4F PEPTIDE; DIVALENT CATION; HIGH DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ANIMAL; ARTICLE; CELL LINE; CHEMISTRY; DRUG EFFECT; ENZYME ACTIVATION; GEL CHROMATOGRAPHY; HUMAN; KINETICS; METABOLISM; MOUSE; WESTERN BLOTTING;

ANIMALS; APOLIPOPROTEIN A-I; ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, WESTERN; CATIONS, DIVALENT; CELL LINE; CHROMATOGRAPHY, GEL; ENZYME ACTIVATION; HUMANS; KINETICS; LIPOPROTEINS, HDL; MICE; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE;

EID: 70350441792     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.5.489     Document Type: Article

References (40)

1. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995; 36:211-28.
2. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004; 95:764-72.
3. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res. 2006; 98:1352-64.
4. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A. 2004; 101:9774-9.
5. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996; 271:518-20.
6. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986; 232:34-47.
7. Rubin EM, Ishida BY, Clift SM, Krauss RM. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc Natl Acad Sci U S A. 1991; 88:434-8.
8. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest. 1994; 94:899-903.
9. Shah PK, Yano J, Reyes O, Chyu KY, Kaul S, Bisgaier CL, et al. High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation. 2001; 103:3047-50.
10. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation. 1999; 100:1816-22.
11. Chiesa G, Sirtori CR. Use of recombinant apolipoproteins in vascular diseases: the case of apoA-I. Curr Opin Investig Drugs. 2002; 3:420-6.
12. Ameli S, Hultgardh-Nilsson A, Cercek B, Shah PK, Forrester JS, Ageland H, et al. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation. 1994; 90:1935-41.
13. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-I Milano on coro-nary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. Jama. 2003; 290:2292-300.
14. Eisenberg S. High density lipoprotein metabolism. J Lipid Res. 1984; 25:1017-58.
15. Sethi AA, Amar M, Shamburek RD, Remaley AT. Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis. Curr Opin Investig Drugs. 2007; 8:201-12.
16. Spagnuolo MS, Cigliano L, D'Andrea LD, Pedone C, Abrescia P. Assignment of the binding site for haptoglobin on Apolipoprotein A-I. J Biol Chem. 2005; 280:1193-98.
17. Sviridov D, Hoang A, Sawyer WH, Fidge NH. Identification of a sequence of apolipoprotein A-I associated with the activation of Lecithin:Cholesterol acyltransferase. J Biol Chem. 2000; 275:19707-12.
18. Kypreos KE, Zannis VI. Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT. Biochem J. 2007; 403:359-67.
19. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992; 71:343-53.
20. Kodali S, Galgoci A, Young K, Painter R, Silver LL, Herath KB, et al. Determination of selectivity and efficacy of fatty acid synthesis inhibitors. J Biol Chem. 2005; 280:1669-77.
21. Datta G, Chaddha M, Hama S, Navab M, Fogelman AM, Garber DW, et al. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res. 2001; 42:1096-104.
22. Fielding CJ, Shore VG, Fielding PE. Lecithin: cholesterol acyltransferase: effects of substrate composition upon enzyme activity. Biochim Biophys Acta. 1972; 270:513-8.
23. Jonas A. Lecithin cholesterol acyltransferase. Biochim Biophys Acta. 2000; 1529:245-56.
24. Guerin M, Dachet C, Goulinet S, Chevet D, Dolphin PJ, Chapman MJ, et al. Familial lecithin:cholesterol acyltransferase deficiency: molecular analysis of a compound heterozygote: LCAT (Arg147 --> Trp) and LCAT (Tyr171 --> Stop). Atherosclerosis. 1997;131:85-95.
25. Funke H, von Eckardstein A, Pritchard PH, Albers JJ, Kastelein JJ, Droste C, et al. A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity. Proc Natl Acad Sci U S A. 1991; 88:4855-9.
26. Solajic-Bozicevic N, Stavljenic A, Sesto M. Lecithin:cholesterol acyltransferase activity in patients with acute myocardial infarction and coronary heart disease. Artery. 1991; 18:326-40.
27. Rader DJ, Ikewaki K, Duverger N, Schmidt H, Pritchard H, Frohlich J, et al. Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase deficiency and fish-eye disease. J Clin Invest. 1994; 93:321-30.
28. Solajic-Bozicevic N, Stavljenic-Rukavina A, Sesto M. Lecithin-cholesterol acryltransferase activity in patients with coronary artery disease examined by coronary angiography. Clin Investig. 1994; 72:951-6.
29. Berard AM, Foger B, Remaley A, Shamburek R, Vaisman BL, Talley G, et al. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med. 1997; 3:744-9.
30. Hoeg JM, Santamarina-Fojo S, Berard AM, Cornhill JF, Herderick EE, Feldman SH, et al. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci U S A. 1996; 93:11448-53.
31. Brousseau ME, Kauffman RD, Herderick EE, Demosky SJJr., Evans W, Marcovina S, et al. LCAT modulates atherogenic plasma lipoproteins and the extent of atherosclerosis only in the presence of normal LDL receptors in transgenic rabbits. Arterioscler Thromb Vasc Biol. 2000; 20:450-8.
32. Ng DS. Insight into the role of LCAT from mouse models. Rev Endocr Metab Disord. 2004; 5:311-8.
33. Zannis VI, Chroni A, Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med. 2006; 84:276-94.
34. Salvatore A, Cigliano L, Bucci EM, Corpillo D, Velasco S, Carlucci A, Pedone C, Abrescia P. Haptoglobin binding to apolipoprotein A-I prevents damage from hydroxyl radicals on its stimulatory activity of the enzyme lecithin-cholesterol acyl-transferase. Biochemistry. 2007; 46:11158-68.
35. Davit-Spraul A, Therond P, Leroy A, Palmade-Rieunier F, Rousset C, Moatti N, Legrand A. Inhibition of lecithin cholesterol acyltransferase by phosphatidylcholine hydroperoxides. FEBS Lett. 1999; 447:106-10.
36. Subbaiah PV, Liu M. Disparate effects of oxidation on plasma acyltransferase activities: inhibition of cholesterol esterification but stimulation of transesterification of oxidized phospholipids. Biochim Biophys Acta. 1996; 1301:115-26.
37. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, et al. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 2004; 109:3215-20.
38. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM. Mechanisms of disease: proatherogenic HDL--an evolving field. Nat Clin Pract Endocrinol Metab. 2006; 2:504-11.
39. Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G, et al. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 2002; 105:290-2.
40. Wang J, Soisson SM, Young K, Shoop W, Kodali S, Galgoci A, et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature. 2006; 441:358-61.